The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and/or concomitant hepatic impairment

Journal of Clinical Pharmacology

Volumn 42, Issue 12, 2002, Pages 1318-1325

  Tammara, Brinda ^a   Trang, John M ^b   Kitani, Mami ^c   Miyamoto, Gohachiro ^c   Bramer, Steven L ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b PK/PD International Inc   (United States)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CAFFEINE; INDOCYANINE GREEN; IOTALAMIC ACID; OPC 18750; PARAXANTHINE; TOBORINONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; ISOMER; KIDNEY DYSFUNCTION; LIVER BLOOD FLOW; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; OPEN STUDY; SINGLE DRUG DOSE;

ADULT; AGED; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INDICATORS AND REAGENTS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; QUINOLONES; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 18744382122     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002042012011     Document Type: Article

References (7)

1. Packer M: Proposed FDA Guidelines for the Clinical Evaluation of Drugs for the Treatment of Congestive Heart Failure. Draft Edition, December 7, 1987.
2. Braunwald E: Historical overview and pathophysiological considerations, in: Braunwald E, Mock MB, Watson JT (eds.), Congestive Heart Failure. New York: Grune & Stratton, 1981;3-9.
3. Veronese L, Rautaureau J, Sadler BM, Gillotin C, Petite JP, Pillegand B, Delvaux M, Masliah C, Fosse S, Lou Y, Stein DS: Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrobial Agents and Chemotherapy 2000;44(4):821-826.
4. Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C: Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clinical Pharmacology and Therapeutics 2001;70(5):425-430.
5. Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data, in: Evans WE, Jusko WJ, Schentag JJ (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd Ed. Vancouver, WA: Applied Therapeutics, 1992;1-43.
6. Gaspari F, Mosconi L, Vigano G, Perico N, Torre L, Virotta G, Bertocchi C, Remuzzi G, Ruggenti P: Measurement of GFR with a single intravenous injections of non-radioactive iothalamate. Kidney International 1992;41(4):1081-1084.
7. Calatayud O, Rodriguez M, Sanchez-Alacaraz A, Ibanez P: Caffeine test assessment for measuring liver function in critically ill subjects. J Clin Pharm Ther 1995;20(1):23-29.